| Prev Close | 6.88 |
| Open | 6.90 |
| Day Low/High | 6.48 / 6.96 |
| 52 Wk Low/High | 5.21 / 22.20 |
| Volume | 539.53K |
| Avg Volume | 696.60K |
| Exchange | NASDAQ |
| Shares Outstanding | 40.46M |
| Market Cap | 288.50M |
| EPS | -2.10 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Advaxis' Axalimogene Filolisbac Data Selected For Poster Presentation At ESGO 2017
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that the European Society of Gynaecologic Oncology (ESGO) has accepted an abstract for a poster...
First Week of August 18th Options Trading For Advaxis (ADXS)
Investors in Advaxis Inc saw new options begin trading this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ADXS options chain for the new August 18th contracts and identified the following put contract of particular interest.
Advaxis To Present At 2017 BIO International Convention
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that Ranya Dajani, Vice President, Business Development, will present a company overview at the 2017...
Advaxis Enters Oversold Territory (ADXS)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Advaxis To Be Featured On Worldwide Business With Kathy Ireland®
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that Advaxis will be featured on Worldwide Business with kathy ireland ® on Sunday, June 18.
Advaxis Details Registrational Trials, EU Regulatory And Commercial Plans At Annual Investor & Analyst Day
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, held its annual Investor & Analyst Day this week with clinical investigators and company leaders providing updates and...
Advaxis To Webcast Investor & Analyst Day 2017
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that its annual Investor & Analyst Day, scheduled for Monday, June 12, 2017 at 1:00 p.
Update: Webcast Of Advaxis Presentation At Jefferies 2017 Global Healthcare Conference Now Available
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, announced that Daniel J.
Advaxis To Present At Jefferies 2017 Global Healthcare Conference
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that Daniel J.
Synthetic Genomics Launches CGMP Suite For Pharmaceutical Quality Manufacturing Of Synthetic DNA For Advaxis' Clinical Trials
Customized suite to support Phase 1 study of Advaxis' personalized cancer immunotherapy
Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration
Array BioPharma, Advaxis, Merrimack Pharmaceuticals and Insys Therapeutics were among the biotech stock movers in premarket trading on Tuesday.
Advaxis And Bristol-Myers Squibb Announce Clinical Collaboration To Evaluate ADXS-DUAL And Opdivo (nivolumab) In Metastatic Cervical Cancer
Advaxis, Inc. (NASDAQ:ADXS) and Bristol-Myers Squibb (NYSE:BMY) today announced a clinical development collaboration to evaluate ADXS-DUAL, an investigational immunotherapy targeting HPV-associated cancers, and...
Advaxis To Host Investor & Analyst Day On June 12
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that it will host its annual Investor & Analyst Day on Monday, June 12, at 1:00 p.
Advaxis Provides Phase 1 Data Of Higher Dose Axalimogene Filolisbac
Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today published online a poster previously presented at the National Cancer Research Institute (NCRI) Cancer Conference in...
Erin Andrews To Participate In Cervical Cancer Educational Forum Hosted By Sylvester Comprehensive Cancer Center And Gilda's Club, Sponsored By Advaxis
Erin Andrews, host of ABC's Dancing with the Stars, reporter with Fox Sports and cervical cancer survivor, will be a special guest at a forum designed to provide patients and families with an overview of the impact of...
Commit To Buy Advaxis At $7.50, Earn 16.4% Annualized Using Options
Investors eyeing a purchase of Advaxis Inc stock, but tentative about paying the going market price of $8.69/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $7.50 strike, which has a bid at the time of this writing of 90 cents.
Advaxis Recognized As One Of New Jersey's "Best Places To Work 2017"
Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, was named to NJBIZ's 2017 Best Places to Work in New Jersey list, as compiled and ranked by the Best Companies Group (BCG).
Short Interest Moves 13.6% Higher For ADXS
The most recent short interest data has been released for the 03/31/2017 settlement date, which shows a 1,212,760 share increase in total short interest for Advaxis Inc , to 10,115,830, an increase of 13.62% since 03/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
These 5 Stocks Under $10 Could Explode Up Soon
Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.
